Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Achilles Therapeutics PLC ADR stock

Learn how to easily invest in Achilles Therapeutics PLC ADR stock.

Achilles Therapeutics PLC ADR is a biotechnology business based in the US. Achilles Therapeutics PLC ADR shares (ACHL) are listed on the NASDAQ and all prices are listed in US Dollars. Achilles Therapeutics PLC ADR employs 242 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Achilles Therapeutics PLC ADR

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ACHL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Achilles Therapeutics PLC ADR stock price (NASDAQ: ACHL)

Use our graph to track the performance of ACHL stocks over time.

Achilles Therapeutics PLC ADR shares at a glance

Information last updated 2022-07-02.
Latest market close$2.49
52-week range$1.84 - $10.54
50-day moving average $2.40
200-day moving average $4.17
Wall St. target price$14.33
PE ratio 0.4415
Dividend yield $0 (0%)
Earnings per share (TTM) $5.64

Buy Achilles Therapeutics PLC ADR shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you open a Robinhood account
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Achilles Therapeutics PLC ADR stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Achilles Therapeutics PLC ADR price performance over time

Historical closes compared with the close of $2.49 from 2022-07-01

1 week (2022-06-28) -3.86%
1 month (2022-06-03) 0.40%
3 months (2022-04-05) -11.39%
6 months (2022-01-05) -44.91%
1 year (2021-07-02) -74.33%
2 years (2020-07-01) N/A
3 years (2019-07-01) N/A
5 years (2017-07-01) N/A

Is Achilles Therapeutics PLC ADR stock undervalued or overvalued?

Valuing Achilles Therapeutics PLC ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Achilles Therapeutics PLC ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Achilles Therapeutics PLC ADR's P/E ratio

Achilles Therapeutics PLC ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Achilles Therapeutics PLC ADR shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Achilles Therapeutics PLC ADR's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

Achilles Therapeutics PLC ADR financials

Gross profit TTM $0
Return on assets TTM -17.42%
Return on equity TTM -29.04%
Profit margin 0%
Book value $6.54
Market capitalisation $101.5 million

TTM: trailing 12 months

Achilles Therapeutics PLC ADR share dividends

We're not expecting Achilles Therapeutics PLC ADR to pay a dividend over the next 12 months.

Achilles Therapeutics PLC ADR overview

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom. .

Frequently asked questions

What percentage of Achilles Therapeutics PLC ADR is owned by insiders or institutions?
Currently 4.924% of Achilles Therapeutics PLC ADR shares are held by insiders and 72.063% by institutions.
How many people work for Achilles Therapeutics PLC ADR?
Latest data suggests 242 work at Achilles Therapeutics PLC ADR.
When does the fiscal year end for Achilles Therapeutics PLC ADR?
Achilles Therapeutics PLC ADR's fiscal year ends in December.
Where is Achilles Therapeutics PLC ADR based?
Achilles Therapeutics PLC ADR's address is: 245 Hammersmith Road, London, United Kingdom, W6 8PW
What is Achilles Therapeutics PLC ADR's ISIN number?
Achilles Therapeutics PLC ADR's international securities identification number is: US00449L1026

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site